Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 1

Status

Withdrawn 2Terminated 2Completed 2

Sponsor Class

OTHER 6INDUSTRY 3NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 5Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 55Recurrence 6Lymphoma, Mantle-Cell 5Leukemia, Myeloid, Acute 5Waldenstrom Macroglobulinemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Immunoglobulin Light-chain Amyloidosis 4Neoplasms, Plasma Cell 3Lymphoma 3Plasmacytoma 2Neoplasms 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2Leukemia, Biphenotypic, Acute 2Carcinoma, Renal Cell 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Proteostasis Deficiencies 1Plasmablastic Lymphoma 1POEMS Syndrome 1Neurofibrosarcoma 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1

Interventions

Cyclophosphamide 115Dexamethasone 70fludarabine phosphate 57Cytarabine 56fludarabine 52Rituximab 51Peripheral Blood Stem Cell Transplantation 40Etoposide 40Gemcitabine 39Lenalidomide 38pembrolizumab 33Radiotherapy 33Busulfan 33Filgrastim 32Carboplatin 31Methotrexate 30Cyclosporine 29Cisplatin 29Bortezomib 29Mycophenolic Acid 28Melphalan 28venetoclax 27Paclitaxel 26Whole-Body Irradiation 24Antilymphocyte Serum 23Temozolomide 22Granulocyte Colony-Stimulating Factor 20Calcium Dobesilate 20Bevacizumab 20Tacrolimus 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × Recurrence × ixazomib × Clear all
NCT02461888 2025-12-17

MUKEight

University of Leeds

Phase 2 Completed
112 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT06050512 2024-11-19

Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

University of Pittsburgh

Phase 1/2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

NCT02499081 2021-06-11

UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment

University of Arkansas

Phase 2 Completed
20 enrolled 9 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT03492138 2020-05-29

Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Icahn School of Medicine at Mount Sinai

Phase 1/2 Terminated
5 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT01887587 2020-01-22

Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

Medical College of Wisconsin

Phase 1 Terminated
5 enrolled 9 charts
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02578121 2017-01-23

UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination

University of Arkansas

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡